Skip to main content
. 2011 Feb 14;17(6):760–765. doi: 10.3748/wjg.v17.i6.760

Table 2.

Distribution of N-acetyltransferase 2 polymorphism and the risk of cancer

Genetic polymorphism NAT2a Cancer, n (%) Control, n (%) P OR (95% CI)
All 147 212
Mx/Mx 88 (59.8) 110 (51.9) 0.19 1
W/Mx 44 (30.0) 83 (39.1) 0.66 (0.42-1.05)
W/W 15 (10.2) 19 (8.9) 0.99 (0.47-2.05)
Slow 88 (59.8) 110 (51.9) 0.17 1.38 (0-2.12)
Fast 59 (40.1) 102 (48.1)
Female 76 127
Mx/Mx 42 (55.2) 58 (45.6) 0.07 1
W/Mx 23 (30.2) 58 (45.6) 0.55 (0.29-1.02)
W/W 11 (14.4) 11 (8.6) 1.38 (0.55-3.48)
Slow 42 (55.2) 58 (45.6) 0.24 1.47 (0.83-2.60)
Fast 34 (44.7) 69 (54.3)
Male 71 85
Mx/Mx 46 (64.8) 52 (61.1) 0.67 1
W/Mx 21 (29.5) 25 (29.4) 0.95 (0.47-1.92)
W/W 4 (5.6) 8 (9.4) 0.57 (0.16-2.00)
Slow 46 (64.7) 52 (61.1) 0.76 0.86 (0.45-1.65)
Fast 25 (35.2) 33 (38.9)
a

Homozygous individuals with genotype W/W, and heterozygote W/Mx, are grouped into fast acetylation phenotype, while homozygous Mx/Mx are grouped in slow acetylators. The percentages of data are in parentheses. NAT2: N-acetyltransferase 2; OR: Odds ratio; 95% CI: Confidence interval.